
浏览全部资源
扫码关注微信
南方医科大学南方医院药学部,广州 510080
硕士。研究方向:药动学。E-mail:work_Zhh@163.com
主任药师,硕士生导师,博士。研究方向:药动学、中药药理。E-mail:wangcx@smu.edu.cn
收稿日期:2023-06-07,
修回日期:2023-08-28,
录用日期:2023-08-30,
纸质出版日期:2023-09-30
移动端阅览
郑晖晖,周龙玥,赵博欣,等.抑乳调经颗粒对奥氮平在大鼠体内药动学的影响[J].中国药房,2023,34(18):2182-2186.
ZHENG Huihui,ZHOU Longyue,ZHAO Boxin,et al.Effects of Yiru tiaojing granules on the pharmacokinetics of olanzapine in rats[J].ZHONGGUO YAOFANG,2023,34(18):2182-2186.
郑晖晖,周龙玥,赵博欣,等.抑乳调经颗粒对奥氮平在大鼠体内药动学的影响[J].中国药房,2023,34(18):2182-2186. DOI: 10.6039/j.issn.1001-0408.2023.18.02.
ZHENG Huihui,ZHOU Longyue,ZHAO Boxin,et al.Effects of Yiru tiaojing granules on the pharmacokinetics of olanzapine in rats[J].ZHONGGUO YAOFANG,2023,34(18):2182-2186. DOI: 10.6039/j.issn.1001-0408.2023.18.02.
目的
2
探讨抑乳调经颗粒对奥氮平在大鼠体内药动学的影响。
方法
2
分别按单剂量给药和多剂量给药,将SD大鼠随机分4组,每组6只。A、B组大鼠分别单次灌胃奥氮平(5 mg/kg)、奥氮平(5 mg/kg)+抑乳调经颗粒(0.972 g/kg);C、D组大鼠同法给药,每天1次,连续给药14 d。分别在给药前及末次给药后5、15、30 min和1、2、3、6、8、12、24 h于大鼠眼眶静脉丛采血,采用液相色谱-质谱技术测定大鼠的血药浓度,采用DAS 2.0软件计算药动学参数。
结果
2
与A组比较,B组大鼠24 h内的药-时曲线下面积(AUC
0-24 h
)、AUC
0-∞
、峰浓度(
c
max
)均显著降低(
P
<0.05),24 h内的平均滞留时间(MRT
0-24 h
)、MRT
0-∞
、表观清除率(CLz/F)均显著延长(
P
<0.05);C组与D组大鼠的药动学参数比较,差异均无统计学意义(
P
>0.05)。
结论
2
单次联用抑乳调经颗粒会抑制奥氮平在大鼠体内的吸收,长期联用抑乳调经颗粒对奥氮平的药动学过程无明显影响。
OBJECTIVE
2
To investigate the effects of Yiru tiaojing granules on the pharmacokinetics of olanzapine in rats.
METHODS
2
SD rats were randomly divided into 4 groups according to single-dose administration and multiple-dose administration, with 6 rats in each group. Groups A and B were given olanzapine (5 mg/kg) or olanzapine (5 mg/kg)+Yiru tiaojing granules (0.972 g/kg) in a single gavage, and groups C and D were administered with the same method once a day for 14 d. Blood was collected from the orbital venous plexus before administration and 5, 15, 30 min and 1, 2, 3, 6, 8, 12, 24 h after the last administration, respectively. The blood concentration was determined by LC-MS, and the pharmacokinetic parameters were calculated by using DAS 2.0 software.
RESULTS
2
Compared with group A, group B showed a significant decrease in AUC
0-24 h
, AUC
0-∞
and
c
max
(
P
<0.05), and a significant prolongation of MRT
0-24 h
, MRT
0-∞
and CLz/F (
P
<0.05); there was no statistically significant difference in the pharmacokinetic parameters between group C and group D (
P
>0.05).
CONCLUSIONS
2
A single administration of Yiru tiaojing granules can inhibit the absorption of olanzapine in rats, and long-term administration of Yiru tiaojing granules does not have a significant effect on the pharmacokinetic process of olanzapine.
LÄHTEENVUO M , TIIHONEN J . Antipsychotic polypharmacy for the management of schizophrenia:evidence and recommendations [J ] . Drugs , 2021 , 81 ( 11 ): 1273 - 1284 .
SIAFIS S , TZACHANIS D , SAMARA M , et al . Antipsychotic drugs:from receptor-binding profiles to metabolic side effects [J ] . Curr Neuropharmacol , 2018 , 16 ( 8 ): 1210 - 1223 .
FULTON B , GOA K L . Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses [J ] . Drugs , 1997 , 53 ( 2 ): 281 - 298 .
PEUSKENS J , PANI L , DETRAUX J , et al . The effects of novel and newly approved antipsychotics on serum prolactin levels:a comprehensive review [J ] . CNS Drugs , 2014 , 28 ( 5 ): 421 - 453 .
BAPTISTA T , KIN N M , BEAULIEU S , et al . Obesity and related metabolic abnormalities during antipsychotic drug administration:mechanisms,management and research perspectives [J ] . Pharmacopsychiatry , 2002 , 35 ( 6 ): 205 - 219 .
王春霞 , 潘斌 , 刘静 , 等 . 抑乳调经颗粒治疗肾虚肝郁型高泌乳素血症的临床疗效观察 [J ] . 中国药房 , 2009 , 20 ( 18 ): 1421 - 1423 .
HUANG X , REN L , HOU L , et al . Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary [J ] J Ethnopharmacol , 2020 , 257 : 112862 .
MAEDA K , HISAKA A , ITO K , et al . Classification of drugs for evaluating drug interaction in drug development and clinical management [J ] . Drug Metab Pharmacokinet , 2021 , 41 : 100414 .
PERITI P , MAZZEI T , MINI E , et al . Pharmacokinetic drug interactions of macrolides [J ] . Clin Pharmacokinet , 1992 , 23 ( 2 ): 106 - 131 .
LOADMAN P M , BIBBY M C . Pharmacokinetic drug interactions with anticancer drugs [J ] . Clin Pharmacokinet , 1994 , 26 ( 6 ): 486 - 500 .
ARAVAGIRI M , TEPER Y , MARDER S R . Pharmacokinetics and tissue distribution of olanzapine in rats [J ] . Biopharm Drug Dispos , 1999 , 20 ( 8 ): 369 - 377 .
KAPUR S , VANDERSPEK S C , BROWNLEE B A , et al . Antipsychotic dosing in preclinical models is often unre-presentative of the clinical condition:a suggested solution based on in vivo occupancy [J ] . J Pharmacol Exp Ther , 2003 , 305 ( 2 ): 625 - 631 .
CALLAGHAN J T , BERGSTROM R F , PTAK L R , et al . Olanzapine: pharmacokinetic and pharmacodynamic profile [J ] . Clin Pharmacokinet , 1999 , 37 ( 3 ): 177 - 193 .
0
浏览量
174
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621